Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha

被引：23
|
作者：
Verma, Dushyant [1 ]
Kantarjian, Hagop [1 ]
Jain, Nitin [1 ]
Cortes, Jorge [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 07期
关键词：
D O I：
10.1080/10428190802043903
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1399 / 1402
页数：4
相关论文
共 50 条
  • [41] Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Rosti, G
    Trabacchi, E
    Bassi, S
    Bonifazi, F
    De Vivo, A
    Martinelli, G
    Alberti, D
    Fincato, G
    Saglio, G
    Baccarani, M
    HAEMATOLOGICA, 2003, 88 (03) : 256 - 259
  • [42] Imatinib Induced Complete Remission of Psoriasis in a Patient with Chronic Myeloid Leukemia
    Jain, Ankur
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2020, 36 (01) : 198 - 199
  • [43] Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation
    Merante, Serena
    Orlandi, Ester
    Bernasconi, Paolo
    Calatroni, Silvia
    Boni, Marina
    Lazzarino, Mario
    HAEMATOLOGICA, 2005, 90 (07) : 979 - 981
  • [44] Imatinib Induced Complete Remission of Psoriasis in a Patient with Chronic Myeloid Leukemia
    Ankur Jain
    Indian Journal of Hematology and Blood Transfusion, 2020, 36 : 198 - 199
  • [45] Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α
    Branford, Susan
    Hughes, Timothy
    Milner, Alvin
    Koelmeyer, Rachel
    Schwarer, Anthony
    Arthur, Chris
    Filshie, Robin
    Moreton, Susan
    Lynch, Kevin
    Taylor, Kerry
    CANCER, 2007, 110 (04) : 801 - 808
  • [46] Outcome of five patients with chronic myeloid leukemia after imatinib mesylate discontinuation
    Tothova, E.
    Kafkova, A.
    Surova, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 427 - 427
  • [47] Long-term molecular response after discontinuation of interferon-alpha in two patients with chronic myeloid leukaemia
    Mauro, Endri
    BLOOD TRANSFUSION, 2012, 10 (04) : 559 - 559
  • [48] Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia
    Braga, Arthur Gomes Oliveira
    Pagnano, Katia Borgia Barbosa
    Campionia, Dal'Bo Pelegrini
    Lopes, Ana Beatriz Pascoal
    Duarte, Gislaine Oliveira
    Metze, Konradin
    Lorand-Metze, Irene
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 (03) : 268 - 272
  • [49] THE PERCENTAGE OF EFFECTOR POPULATIONS OF NK CELLS CORRELATED HIGHLY WITH SUSTAINED COMPLETE MOLECULAR RESPONSE WITH OR WITHOUT IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS
    Seiichiro, K.
    Izuru, M.
    Takayuki, Y.
    Junichiro, M.
    Junko, O.
    Tetuzo, T.
    Koiti, I.
    Kazuma, O.
    HAEMATOLOGICA, 2013, 98 : 300 - 300
  • [50] LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION
    Latagliata, R.
    Romano, A.
    Mancini, M.
    Breccia, M.
    Carmosino, I.
    Vozella, F.
    Montagna, C.
    Volpicelli, P.
    Petrucci, L.
    Serao, A.
    Molica, M.
    Salaroli, A.
    Diverio, D.
    Tafuri, A.
    Alimena, G.
    HAEMATOLOGICA, 2014, 99 : 330 - 330
12345